Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
LMDX LumiraDx
0.945+0.015+1.61%
Trading Session
01/31 11:28 ET
High
0.950
Open
0.930
Turnover
15.12K
Low
0.920
Pre Close
0.930
Volume
16.14K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
LumiraDx Limited (NASDAQ:LMDX) Short Interest Down 27.6% in December
LumiraDx Limited (NASDAQ:LMDX – Get Rating) saw a large decline in short interest in the month of December. As of December 15th, there was short interest totalling 233,100 shares, a decline of 27.6%
The Goldman Sachs Group Begins Coverage on LumiraDx (NASDAQ:LMDX)
The Goldman Sachs Group initiated coverage on shares of LumiraDx (NASDAQ:LMDX – Get Rating) in a research report report published on Monday, The Fly reports. The brokerage issued a neutral rating on
CNS Pharmaceuticals (NASDAQ:CNSP) & LumiraDx (NASDAQ:LMDX) Head-To-Head Comparison
CNS Pharmaceuticals (NASDAQ:CNSP – Get Rating) and LumiraDx (NASDAQ:LMDX – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based o
LumiraDx (NASDAQ:LMDX) Receives New Coverage From Analysts at The Goldman Sachs Group
The Goldman Sachs Group started coverage on shares of LumiraDx (NASDAQ:LMDX – Get Rating) in a research note released on Monday morning, The Fly reports. The firm issued a neutral rating on the stock
LumiraDx Initiated With a Neutral at Goldman Sachs
LumiraDx Announces Its Fast Lab Solutions Molecular Test Has Been Validated By UK Coronavirus Test Device Approvals
LumiraDx Announces Its Fast Lab Solutions Molecular Test Has Been Validated By UK Coronavirus Test Device Approvals
LumiraDx Gets $14.2 Million Grant From Bill & Melinda Gates Foundation for Tuberculosis Test Development
03:52 AM EST, 12/14/2022 (MT Newswires) -- LumiraDx (LMDX) said Wednesday it has received $14.2 million in grants from the Bill & Melinda Gates Foundation for the development of its molecular tubercul
Press Release: LumiraDx Announces New Investment for Ongoing Development of Its Point of Care Molecular Tuberculosis Test
LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test Company receives $14.2M in grants from the Bill & Melinda Gates Foundation to support the TB
Latest Clinicians' U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing Centers
WALTHAM, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care diagnostics company, today announced findings from its second annual "Point of Care Diagnostics: A
LumiraDx Limited (NASDAQ:LMDX) Sees Large Increase in Short Interest
LumiraDx Limited (NASDAQ:LMDX – Get Rating) was the recipient of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 309,800 shares, a
Company Overview
More
LumiraDX Ltd. is a next-generation point of care diagnostics company, which engages in the provision of an innovative diagnostic platform that supports a menu of tests with lab-comparable performance at the point of care. The firm's diagnostic testing solutions are being deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness as well as disease. It also has a comprehensive portfolio of COVID-19 testing solutions from the lab to point of need. The company was founded by Ronald Zwanziger, David Scott, and Jerry McAleer in 2014 and is headquartered in London, the United Kingdom.
CEO： Mr. Ron Zwanziger
Market： NASDAQ
Listing Date： 03/10/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet